摘要Objective:To explore the interventional effects of renal-targeting peptide-modified ginsenoside Rg3 nanomicelle(GRg3@RT-PMs)on hypertension and vascular calcification in patients with long-term renal dialysis,and to elucidate its potential molecular mechanism,providing a new strategy for the precise treatment of dialysis complications.Methods:GRg3@RT-PMs were prepared using chitosan and ginsenoside Rg3 self-assembly technology modified with a renal-targeted peptide(G3-C12).Their particle size,encapsulation efficiency,and in vitro sustained-release characteristics were characterized.A high-phosphate-induced calcification model of human renal tubular epithelial cells(HK-2)was used to evaluate the targeting ability,biocompatibility,and inhibitory effect of GRg3@RT-PMs on calcification marker proteins(BMP-2,Runx2).A total of 18 dialysis patients were enrolled to assess the effects of oral administration of PMs,GRg3,and GRg3@RT-PMs on blood pressure and arterial calcification.Results:GRg3@RT-PMs had a particle size of(125.3±3.2)nm,an encapsulation efficiency of(89.7±2.3)%,and a cumulative release rate of(82.5±3.1)%over>48 h;GRg3@RT-PMs significantly inhibited the expression of BMP-2 and Runx2 in high-phosphate-induced HK-2 cells(P<0.01);In patients,the systolic blood pressure in the GRg3@RT-PMs group trended toward the normal range and was lower than that in the ginsenoside Rg3 and Rg3/β-CD complex groups,while diastolic blood pressure was more stable(P<0.05);The calcification score in the GRg3@RT-PMs group was lower than that in the Rg3 group after administration(P<0.01).Conclusion:GRg3@RT-PMs effectively alleviated dialysis-related vascular calcification and blood pressure abnormalities through the renal-targeted delivery,demonstrating a potential for clinical translation.